Loading the comparison…
Loading the comparison…
Recovery & Repair
An EPO-derived peptide that protects tissue without raising red blood cells.
Recovery & Repair
The most-discussed healing peptide, built on a stomach-protein fragment.
ARA-290 is not FDA-approved and rated 3/5 for evidence; BPC-157 is not FDA-approved and rated 2/5. ARA-290 has more human evidence behind it. Both are banned in sport by WADA. Both are used for recovery & repair goals.
| Compare | ARA-290 An EPO-derived peptide that protects tissue without raising red blood cells. | BPC-157 The most-discussed healing peptide, built on a stomach-protein fragment. |
|---|---|---|
| Category | Recovery & Repair | Recovery & Repair |
| Evidence | 3/5Small human Phase 2 trials (sarcoidosis small-fiber neuropathy, type 2 diabetes neuropathy). No Phase 3. | 2/5Dozens of rodent studies; only tiny human pilot data (e.g. knee pain retrospective, IV safety pilot). |
| FDA status | Not FDA-approved | Not FDA-approved |
| WADA (sport) | Banned | Banned |
| Also known as | Cibinetide, Helix B surface peptide analog | Body Protection Compound-157, Bepecin, PL 14736 |
| How it works | Activates the 'innate repair receptor' (EPO receptor paired with the beta-common receptor), which calms inflammation and protects nerves. It does not activate the receptor that makes red blood cells, so it does not thicken blood the way EPO does. | Appears to up-regulate growth-factor receptors (VEGFR2, growth hormone receptor), promote new blood vessel formation (angiogenesis), and modulate nitric-oxide signaling. Exact human pharmacology is not established. |
| Half-life | About 2 minutes in plasma; effects last much longer via receptor signaling | Short (hours); effects thought to be local + signaling driven |
| Commonly reported doses |
|
|
| Route | Subcutaneous | Subcutaneous, near injury site |
| Good once mixed | ~28 days in the fridge | ~28 days in the fridge |
| Top side effects |
|
|
| Lowest research-listing price per mg | $3.00 (10 mg vial, 40% off) | $2.40 (10 mg vial, 40% off) |
| Latest lab purity | 99.93% (lot ARA0002) | 99.61% (lot BP0002) |
Want a third? Add another peptide. Doses are commonly reported ranges, not recommendations.
Free for ChatGPT and Claude
Connect MyPeps to ChatGPT or Claude and ask follow-ups about ARA-290 and BPC-157. It answers from these same pages, with links back here.
ARA-290 is not FDA-approved and rated 3/5 for evidence; BPC-157 is not FDA-approved and rated 2/5. ARA-290 has more human evidence behind it. Both are banned in sport by WADA. Both are used for recovery & repair goals.
ARA-290: Not FDA-approved. BPC-157: Not FDA-approved. Regulations change, so confirm with the FDA.
ARA-290 is rated 3 out of 5: Small human Phase 2 trials (sarcoidosis small-fiber neuropathy, type 2 diabetes neuropathy). No Phase 3. BPC-157 is rated 2 out of 5: Dozens of rodent studies; only tiny human pilot data (e.g. knee pain retrospective, IV safety pilot). The scale is explained on our methodology page.
ARA-290 is banned by WADA, by name or as part of a named class. BPC-157 is banned by WADA, by name or as part of a named class.